Associated Papers
Identification of high-risk signatures and therapeutic targets through molecular characterization and immune profiling of TP53-mutant breast cancer.
Paulino PJIV et al.
Journal, Genetic Engineering & Biotechnology, 2025
41386839 (PubMed )
Supplement: mmc5.xlsx › Table_S2
Comprehensive genomic profiling of Taiwanese triple-negative breast cancer samples with medium- and large-sized sequencing panels: A comparative study implicating treatment allocations.
Huang CC et al.
Biomedical Reports, 2025
Strategies for Anticancer Treatment in p53-Mutated Head and Neck Squamous Cell Carcinoma.
Cai BH et al.
Biomedicines, 2025
Genetic Alterations, Therapy Response, and Survival Among Patients With Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Richters L et al.
Jama Network Open, 2025
40009381 (PubMed )
Supplement: jamanetwopen-e2461639-s002.pdf
Cell-free DNA from germline TP53 mutation carriers reflect cancer-like fragmentation patterns.
Wong D et al.
Nature Communications, 2024
The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability.
Abad E et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2024
38685100 (PubMed )
Supplement: 13046_2024_3045_MOESM2_ESM.xlsx › Patient_p53_mutated_samples
Mutation detection in saliva from oral cancer patients.
Ahmed AA et al.
Oral Oncology, 2024
Clinicopathological, immunohistochemical and molecular features of acinic cell carcinoma of the breast.
Yang X et al.
Oncology Letters, 2024
Early Cancer Detection in Li-Fraumeni Syndrome with Cell-Free DNA.
Wong D et al.
Cancer Discovery, 2024
37874259 (PubMed )
Supplement: cd-23-0456_table_s2_suppst2.xlsx › Sheet1
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
36964217 (PubMed )
Supplement: 41598_2023_32092_MOESM1_ESM.xlsx › Suppl._Table_S4
Mosaicism in Tumor Suppressor Gene Syndromes: Prevalence, Diagnostic Strategies, and Transmission Risk.
Chen JL et al.
Annual Review of Genomics and Human Genetics, 2022
36044908 (PubMed )
Supplement: gg23-giannikou_suptable1.xlsx › TP53
P63 and P73 Activation in Cancers with p53 Mutation.
Cai BH et al.
Biomedicines, 2022
TAPES: A tool for assessment and prioritisation in exome studies.
Xavier A et al.
Plos Computational Biology, 2019
31613886 (PubMed )
Supplement: pcbi.1007453.s002.xlsx › SoftVsPanel
Select a paper to view details